Armonk, NY, United States of America

Jonathan A Welt



 

Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2018-2019

Loading Chart...
Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovations by Jonathan A Welt

Introduction

Jonathan A Welt is an accomplished inventor based in Armonk, NY (US). He has made significant contributions to the field of biotechnology, particularly in the development of antibodies for cancer treatment. With a total of 2 patents, his work focuses on targeting B-cell receptor complexes in malignancies.

Latest Patents

Jonathan's latest patents include groundbreaking inventions related to antibodies targeting the membrane bound IgM (mIgM) of the B-cell receptor complex. These inventions are particularly relevant for B-cell lymphomas and leukemias. The first patent discusses the use of anti-B-Cell mIgM antibodies in the treatment of B-cell malignancies. The second patent details monoclonal antibodies designated mAb4-2b, mAb1-1, mAb2-2b, and mAb3-2b, which were produced by hybridoma cell lines. Both patents emphasize the therapeutic potential of these antibodies in combating B-cell malignancies.

Career Highlights

Jonathan A Welt is associated with Welt Bio-molecular Pharmaceutical, LLC, where he continues to innovate in the field of pharmaceuticals. His work has been instrumental in advancing treatments for B-cell related cancers, showcasing his dedication to improving patient outcomes.

Collaborations

Some of Jonathan's notable coworkers include Sydney Welt and David Kostyal. Their collaborative efforts contribute to the ongoing research and development within the company.

Conclusion

Jonathan A Welt's contributions to biotechnology and cancer treatment through his patents highlight the importance of innovation in medicine. His work continues to pave the way for new therapeutic approaches in the fight against B-cell malignancies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…